As part of the International Liver Congress (ILC) 2021, the EASL Takeaways take a look at key topics from the congress, with leading experts discussing the most impactful science and putting it into perspective. In this episode, join Professor Josep Llovet, Professor Maria Reig, and Professor Helen Reeves as they review key abstracts from ILC 2021 on the topic of liver tumours.

Professor Llovet starts the session with four abstracts that explored candidate biomarkers associated with treatment outcomes to immunotherapy, before the experts discuss the clinical implications of these biomarkers in more detail. They also examine some of the concerns raised about sub-optimal responses to immunotherapy observed in non-viral compared to viral HCC patients, particularly NAFLD HCC patients. Professor Reig then takes the experts through some of the clinical trials in immunotherapy that were presented at the congress, specifically on neoadjuvant nivolumab, pembrolizumab and atezolizumab + bevacizumab. 


Josep M. Llovet Josep M Llovet, MD, PhD is Professor of Medicine - Hepatic Oncology at University of Barcelona, Professor of Research ICREA, Head of the Translational Research in Liver Cancer Group, at IDIBAPS-Hospital Clinic Barcelona, and Director of the Mount Sinai Liver Cancer Program and Professor of Medicine, at Icahn School of Medicine at Mount Sinai (New York). His research interest covers the establishment of therapies as standard of care for hepatocellular carcinoma (HCC) – chemoembolization, sorafenib, regorafenib and ramucirumab; provide definitions for molecular and immune classes of HCC and cholangiocarcinoma (CCA) as well as the discovery of drivers as therapeutic targets for HCC and iCCA. Prof Llovet is also a chair and panellist of guidelines for management of HCC for various organizations (EASL, AASLD, ESMO and ILCA).
Helen Reeves Helen Reeves is a Professor of Liver Cancer at the Newcastle University Centre for Cancer and the Newcastle upon Tyne Hospitals NHS Foundation Trust. She is also a scientific committee member for the European Association for Study of the Liver (EASL) and is an active member of the EASL Education Committee and the HCC-UK Committee. Her main research focus and expertise is on HCC in patients with fatty liver disease and on the development of clinically relevant biomarkers.
Maria Reig Maria Reig is a Professor of Medicine in the Liver Unit at Hospital Clinic of Barcelona in Spain, and a member of the European Association for the Study of the Liver (EASL) Scientific Committee. Her expertise and area of interest is the development of prognostic models for patients with liver cancer and evaluation of treatment options with special emphasis in systemic therapy as well as new research about immune modulation and cancer emergence after antiviral treatment.